We describe an extremely severe case of therapy refractory NMDA receptor encephalitis (NMDAe) in a 26-yearold woman. After rituximab, bilateral oophorectomy, repeated cycles of high dose methylprednisolone and plasma exchange, she received repeated cyclophosphamide, tocilizumab (interleukin-6 inhibitor) and finally bortezomib (plasma cell depleting drug) leading to remission after 204 days in intensive care. Two years after disease onset her cognitive functions are still affected, but slowly improving and the cerebral atrophy has been partly reversed. The cerebrospinal fluid biomarker profile suggests an early synaptic/dendritic process, with subsequent neuroaxonal degeneration motivating aggressive treatment early on.
Introduction
NMDA receptor encephalitis (NMDAe) is an antibody-mediated autoimmune disorder, first described as a discrete entity by Dalmau and colleagues after observing four female patients with teratoma and neuropsychiatric symptoms (Vitaliani et al., 2005) . Subsequently, the target antigen was identified as the NR1 subunit of the NMDA-receptor, which is abundantly expressed in the frontal and hippocampal regions of the brain (Dalmau et al., 2007) . NMDAe occurs both as a paraneoplastic and an autoimmune or parainfectious condition, the latter sometimes triggered by herpes simplex encephalitis. NMDAe is likely to be the most common form of the paraneoplastic encephalitides and the most common autoimmune encephalitis second to acute disseminated encephalomyelitis (Granerod et al., 2010) . NMDAe has a wide clinical spectrum; from mild to very severe disease, where mortality rates are as high as 20% (Titulaer et al., 2013) , but specific treatment algorithms remain to be established. A large proportion of patients do not have focal injuries visible on magnetic resonance imaging (MRI), while others display hyperintense lesions predominately in the hippocampi, but also in other areas. In severe cases global brain atrophy, mainly in fronto-temporal regions, may be prominent. In classical forms of paraneoplastic encephalitides, specific nerve cell populations are targeted, leading to loss of neurons and permanent deficits. In contrast, a remarkable finding in a long-term follow-up of two patients with severe NMDAe was that a pronounced fronto-temporal atrophy during the acute phase of the disease was reversible (Iizuka et al., 2010) . The biological basis for this phenomenon is unknown and reports on biomarker profiles in NMDAe are limited but growing (Constantinescu et al., 2016; Liba et al., 2016) .
Case report
A 26-year-old woman of Southeast Asian descent, with no relevant medical family history of autoimmune or psychiatric disease, presented with a rapidly progressing personality disorder, with aggressive behavior, emotional liability, suicidal ideation, visual and auditory hallucinations, insomnia and memory impairment, followed by repeated generalized seizures. Despite initial treatment with antiepileptic drugs (AEDs) she developed status epilepticus and was transferred to neurointensive care. 
